Humana (HUM) Stock Forecast & Price Target

$379.22 -1.51 (-0.40%)

As of 08/21/2026 03:58 PM Eastern

Compare

Humana - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 30 Analyst Ratings

Sell
1

Hold
15

Buy
14

Based on 30 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 30 analysts, 1 has given a sell rating, 15 have given a hold rating, and 14 have given a buy rating for HUM.

Consensus Price Target

$395.22
4.22% Upside

According to the 30 analysts' twelve-month price targets for Humana, the average price target is $395.22. The highest price target for HUM is $513.00, while the lowest price target for HUM is $195.00. The average price target represents a forecasted upside of 4.22% from the current price of $379.22.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HUM Analyst Ratings Over Time

Type	Current Forecast 8/22/25 to 8/22/26	1 Month Ago 7/23/25 to 7/23/26	3 Months Ago 5/24/25 to 5/24/26	1 Year Ago 8/22/24 to 8/22/25
Strong Buy	0 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	15 Hold rating(s)	15 Hold rating(s)	15 Hold rating(s)	15 Hold rating(s)
Sell	1 Sell rating(s)	2 Sell rating(s)	4 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$395.22	$327.17	$263.35	$283.29
Forecasted Upside	4.22% Upside	-17.04% Downside	-14.44% Downside	-5.58% Downside
Consensus Rating	Hold	Hold	Hold	Hold

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Healthcare Companies	Broader Market
Consensus Rating Score	2.43	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	4.22% Upside	833.57% Upside	12.34% Upside
News Sentiment Rating	Positive News See Recent HUM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/14/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
8/11/2026	Zacks Research 5 of 5 stars		Downgrade	Strong-Buy ➝ Hold
8/10/2026	JPMorgan Chase & Co. 3 of 5 stars	Lisa Gill 4 of 5 stars	Boost Target	Neutral	$316.00 ➝ $393.00	+1.60%
8/4/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$249.00 ➝ $370.00	+2.12%
7/31/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$344.00 ➝ $407.00	+11.00%
7/31/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Langston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$350.00 ➝ $370.00	+0.46%
7/30/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Overweight	$463.00	+25.93%
7/30/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A.J. Rice Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy
7/30/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform
7/30/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Hill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Hold
Why major institutions are piling into this digital asset now (Ad) BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. Get the name, the ticker, and exactly how to buy it
7/30/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold
7/30/2026	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy
7/30/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$405.00	+9.57%
7/30/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$390.00	+5.51%
7/30/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$269.00 ➝ $471.00	+28.73%
7/30/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$513.00	+40.21%
7/29/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$480.00	+31.65%
7/29/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Fischbeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$500.00	+37.24%
7/14/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David MacDonald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$320.00 ➝ $415.00	+1.70%
7/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$227.00 ➝ $502.00	+27.81%
7/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$246.00 ➝ $415.00	+3.54%
7/7/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$264.00 ➝ $300.00	-23.66%
6/8/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$335.00 ➝ $390.00	+11.39%
6/3/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$425.00	+32.57%
5/20/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
5/20/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy
5/20/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy
4/30/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Sell	$158.00 ➝ $195.00	-18.29%
12/12/2025	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sector Weight
10/9/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Fidel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Equal Weight	$250.00 ➝ $250.00	+2.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:59 AM ET.

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 19, 2026. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

The current stock price is around $382, reflecting a strong performance in the health insurance sector.
Humana Inc. reported a significant year-over-year revenue increase of over 26%, indicating robust growth and demand for its services.
The company has consistently beaten earnings expectations, with recent earnings per share surpassing analyst estimates, showcasing effective management and operational efficiency.
With a return on equity of 11.20%, Humana Inc. demonstrates effective use of shareholder funds to generate profits, which is attractive to investors looking for solid returns.
The company has a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging debt for growth while maintaining financial stability.

Humana
Bear Case

Investors should be bearish about investing in Humana Inc. for these reasons:

The stock has a relatively high PE ratio of 36.15, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
Despite strong revenue growth, the net margin of 0.88% suggests that profitability may be under pressure, which could affect future earnings.
Analysts have mixed ratings on the stock, with some suggesting caution, which may indicate uncertainty about its future performance.
The beta of 0.72 indicates lower volatility compared to the market, which may limit potential gains for investors seeking high-risk, high-reward opportunities.
With a PEG ratio of 2.23, the stock may not be as attractive for growth investors, as it suggests that the stock price is high relative to its expected growth rate.

HUM Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $395.22, with a high forecast of $513.00 and a low forecast of $195.00.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There is currently 1 sell rating, 15 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.

According to analysts, Humana's stock has a predicted upside of 4.22% based on their 12-month stock forecasts.

Over the previous 90 days, Humana's stock had 12 upgrades and 4 downgrades by analysts.

Humana has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore, Guggenheim, HSBC, JPMorgan Chase & Co., Lake Street Capital, Leerink Partners, Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like Humana more than other "healthcare" companies. The consensus rating score for Humana is 2.43 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how HUM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Humana Recommendations

This page (NYSE:HUM) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humana (HUM) Stock Forecast & Price Target

Humana - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HUM Analyst Ratings Over Time

HUM Analyst Recommendations By Month

HUM Price Targets by Month

Humana Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Humana Stock? HUM Pros and Cons Explained

Humana
Bull Case

Humana
Bear Case

HUM Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Humana Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humana (HUM) Stock Forecast & Price Target

Humana - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HUM Analyst Ratings Over Time

HUM Analyst Recommendations By Month

HUM Price Targets by Month

Humana Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Humana Stock? HUM Pros and Cons Explained

Humana Bull Case

Humana Bear Case

HUM Forecast - Frequently Asked Questions

What is Humana's forecast for 2026?

Should I buy or sell Humana stock right now?

Does Humana's stock price have much upside?

Has Humana been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Humana?

Do Wall Street analysts like Humana more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Humana Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Humana
Bull Case

Humana
Bear Case